Admilparant

Intervention Phase 3

1 paper

2 trials, 2 about aging

2 of 2 trials sponsored by its developers

Trials

2 about aging, of 2

About aging

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
Phase 3Active, not recruiting
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
Phase 3Active, not recruiting

Development

Companies: Bristol Myers SquibbPhase 3idiopathic pulmonary fibrosis, progressive pulmonary fibrosis

Trial sponsors

Bristol Myers Squibb
Company2 trialsPhase 32,312 people

Latest

1 in 12 months

Frontiers in MedicineMay 7

Beyond attenuation: a translational review of curative-intent pharmacological targets in idiopathic pulmonary fibrosis

ReviewIdiopathic pulmonary fibrosis